US-based Maxor Specialty Pharmacy, a VytlOne company, and a pharmacy solutions partner, announced on Wednesday that it has been selected by New Jersey-based biotech company Insmed to be a limited distribution provider of Brinsupri.
Brinsupri is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and paediatric patients 12 years of age and older.
The company said brinsupri is the latest addition to a growing number of limited distribution products available through VytlOne.
"We are excited to partner with Insmed for the launch of Brinsupri, the first FDA-approved medication for the treatment of bronchiectasis," said Joel Wright, president, VytlOne Pharmacy Services. "This milestone underscores our commitment to the rare disease community, and we are honoured to play a role in the improvement of the lives of our bronchiectasis patients."
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval